BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...said Tuesday that FDA and EMA both accepted marketing applications in their respective regions for IL-17A/F...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

This is the third article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
BioCentury | Aug 27, 2020
Distillery Therapeutics

IL-25 to mitigate GvHD in the GI tract after transplant

DISEASE CATEGORY: Transplant INDICATION: Graft-versus-host disease (GvHD) IL-25 could protect against gastrointestinal GvHD by reducing the loss of goblet cells, which contribute to barrier function through mucus and antimicrobial peptide production. In patients who had...
BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline

...COVID-19.The researchers found that PTC299 also suppresses the production of inflammatory cytokines such as IL-6, IL-17A...
...governments.TARGETSCRP - C-reactive protein DHODH - Dihydroorotate dehydrogenase IL-6 - Interleukin-6 IL-8 (CXCL8) - Interleukin-8 IL-17A...
...Trust Mannan binding lectin serine peptidase 2 (MASP2) Interleukin-6 (IL-6) Interleukin-8 (IL-8) (CXCL8) C-reactive protein (CRP) Lactate dehydrogenase (LDH) Dihydroorotate dehydrogenase (DHODH) Interleukin-17A (IL-17A) Interleukin-17F...
BioCentury | May 19, 2020
Emerging Company Profile

Helmed by OrbiMed’s Wang, Inmagene debuts with Phase II autoimmune program

...Ltd. (NASDAQ:ZLAB) and I-Mab Biopharma (NASDAQ:IMAB). On Friday, the company gained commercialization rights to protein-based IL-17A...
...Phase II/III trial by year-end. IMG-020 is capable of simultaneously binding both subunits of the IL-17A...
...Jonathan Wang Patents: Undisclosed Targets IL-17A - Interleukin-17A IL17R (IL17RA) - Interleukin-17 receptor Hongjiang Li, Staff Writer ABY-035 Interleukin-17A (IL-17A) Inmagene...
BioCentury | Apr 24, 2020
Product Development

Upbeat Lilly earnings come with positive psoriasis results, delays for two autoimmune programs

...from the Phase III OASIS-2 study of the IL23P19 inhibitor -- a head-to-head trial against IL-17A...
BioCentury | Mar 31, 2020
Deals

Lilly gains rights to Sitryx’s two most advanced immunometabolic programs in four-target deal

...goes well, Weir said. Lilly markets immunology drugs Taltz ixekizumab, which is an antagonist of IL-17A...
BioCentury | Jan 11, 2020
Targets & Mechanisms

Colitis-associated somatic mutations yield new colorectal cancer target

Kyoto University team identifies colitis-associated somatic mutations that are lost in colitis-associated cancer to reveal a new colorectal cancer target. A Japanese team has identified novel colorectal cancer targets by contrasting somatic mutations in cancerous...
BioCentury | Dec 7, 2019
Company News

Dec. 6 Company Quick Takes: Alexion rebuffs activist’s push for sale; plus UCB, Genmab, Enzyvant, Biohaven

...S.A. (Euronext:UCB) plans to submit regulatory applications in mid-2020 for bimekizumab after the mAb against IL-17A...
...agent riluzole to improve cognitive function or hippocampal volume vs. placebo at 26 weeks. Targets: IL-17A...
...UCB4940) Darzalex, daratumumab (JNJ-54767414, humax-cd38) UCB S.A. Genmab A/S Biohaven Pharmaceutical Holding Co. Ltd. Johnson & Johnson Alexion Pharmaceuticals Inc. Enzyvant Sciences GmbH Interleukin-17A (IL-17A) Interleukin-17F...
BioCentury | Nov 14, 2019
Company News

Via Allergan hair loss deal, Exicure builds balance sheet to advance oncology, neurology pipeline

A collaboration deal giving Allergan options to obtain rights to Exicure's hair loss programs will provide the biotech with non-dilutive cash to further advance a pipeline of spherical nucleic acid (SNA) therapeutics for oncology, neurology...
Items per page:
1 - 10 of 411